Nanjing Vazyme Biotech Co Ltd (688105) — Capital Reinvestment Ratio
Nanjing Vazyme Biotech Co Ltd (688105) has a Capital Reinvestment Ratio of 0.21x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥75.30 Million) in capital expenditures (CN¥15.83 Million). Check tangible equity quality of Nanjing Vazyme Biotech Co Ltd to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Nanjing Vazyme Biotech Co Ltd Capital Reinvestment Ratio (2019–2025)
This chart tracks Nanjing Vazyme Biotech Co Ltd's Capital Reinvestment Ratio across 6 annual periods. For the full cash flow conversion analysis, see 688105 cash generation efficiency.
Annual Capital Reinvestment Ratio for Nanjing Vazyme Biotech Co Ltd (2019–2025)
Year-by-year Capital Reinvestment Ratio for Nanjing Vazyme Biotech Co Ltd from 2019 to 2025. See Nanjing Vazyme Biotech Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.20x | CN¥233.16 Million | CN¥47.39 Million | ▼ -82.7% |
| 2023 | 1.17x | CN¥198.40 Million | CN¥232.90 Million | ▼ -10.4% |
| 2022 | 1.31x | CN¥735.17 Million | CN¥962.86 Million | ▲ +208.4% |
| 2021 | 0.42x | CN¥616.80 Million | CN¥261.96 Million | ▲ +123.7% |
| 2020 | 0.19x | CN¥803.55 Million | CN¥152.54 Million | ▼ -85.5% |
| 2019 | 1.31x | CN¥15.20 Million | CN¥19.88 Million | — |